2023-507377-17-00招募中1 期
A Phase 1b, Randomized, Open-Label Trial to Evaluate Safety, Engraftment, and Initial Signs of Clinical Activity of MB097 in Combination with Pembrolizumab in Melanoma Patients with Primary Resistance to an Anti-PD-1-Containing Immunotherapy (MELODY-1)
Microbiotica Limited12 个研究点 分布在 3 个国家目标入组 27 人开始时间: 2024年7月22日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 27
- 试验地点
- 12
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Microbiotica Information
Scientific
Microbiotica Limited
研究点 (12)
Loading locations...
相似试验
进行中（未招募）
1 期
Clinical trial with MBK-01, intestinal microbiota capsules, for the treatment of patients with recurring diverticulitisCTIS2023-506224-87-00Mikrobiomik Healthcare Company S.L.81
进行中（未招募）
1 期
A Phase IIIb, randomised, open label study to compare the safety, efficacy and tolerability of anagrelide hydrochloride versus hydroxyurea in high-risk essential thrombocythaemia patients.Essential thrombocythaemia (ET)MedDRA version: 7.1Level: LLTClassification code 10015493EUCTR2004-004061-15-ESShire Pharmaceutical Development Ltd.146
进行中（未招募）
1 期
A Phase IIIb, randomised, open label study to compare the safety, efficacy and tolerability of anagrelide hydrochloride versus hydroxyurea in high-risk essential thrombocythaemia patients.Essential thrombocythaemia (ET)MedDRA version: 7.1Level: LLTClassification code 10015493EUCTR2004-004061-15-IEShire Pharmaceutical Development Ltd.184
进行中（未招募）
不适用
A Phase IIIb, randomised, open label study to compare the safety, efficacy and tolerability of anagrelide hydrochloride versus hydroxyurea in high-risk essential thrombocythaemia patients.Essential thrombocythaemiaMedDRA version: 12.0Level: LLTClassification code 10015493Term: Essential thrombocythaemiaEUCTR2004-004061-15-PLShire Pharmaceutical Development Ltd.184
进行中（未招募）
1 期
A Phase IIIb, randomised, open label study to compare the safety, efficacy and tolerability of anagrelide hydrochloride versus hydroxyurea in high-risk essential thrombocythaemia patients.EUCTR2004-004061-15-BEShire Pharmaceutical Development Ltd.146